AbbVie Unveils New Clinical Trials for Immunology Treatments at AAD 2026

On March 27, 2026, AbbVie (NYSE: ABBV) announced significant new developments at the American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado. This year, AbbVie is showcasing a total of 24 abstracts, emphasizing their commitment to enhancing standard treatment practices for immunological skin diseases. Among these, one will be a late-breaking presentation featuring essential data that further solidifies AbbVie's leadership in this field.

The new studies presented cover a spectrum of conditions, including psoriasis and psoriatic arthritis, underscoring the efficacy and safety of Risankizumab and Upadacitinib. According to Dr. Andrew Anisfeld, AbbVie's Vice President of Global Medical Affairs in Immunology, the data presented will highlight the ongoing efforts to redefine standard treatments, ultimately aiming to transform the treatment landscape for patients with immune-mediated skin disorders.

Key Highlights from the Presentation

Long-Term Efficacy of Risankizumab

In the domain of psoriatic arthritis, AbbVie shared compelling evidence regarding the long-term structural progression suppression seen in patients administered Risankizumab. Data from the Phase 3 KEEPsAKE-1 trial demonstrated that 88% of patients maintained radiographic non-progression for as long as five years, showcasing the medication's lasting effectiveness.

Safety and Efficacy of Upadacitinib in Atopic Dermatitis

Three Phase 3 studies highlighted the long-term safety profile of Upadacitinib, administered over a period of up to six years to adolescents and adults suffering from moderate to severe atopic dermatitis. The results were stratified by age to assess the safety outcomes. Overall, 2,683 patients were analyzed, representing more than 9,000 patient-years of exposure. Notably, the incidence of specific adverse events consistently remained stable across the younger demographic, while some events were observed with a higher frequency in older patients (65 years and above).

Quality of Life Improvements

The presentation also included intriguing real-world evidence demonstrating how Upadacitinib treatment significantly improved quality of life indicators among patients. Results from the AD-VISE study revealed that a higher percentage of patients achieved minimal disease activity compared to those meeting moderate treatment goals. This was measured using the Dermatology Life Quality Index (DLQI), indicating a significant positive impact on the patients' overall quality of life.

Addressing Challenging Ailments

Psoriasis affecting sensitive areas, such as the genitals and scalp, was also rigorously studied. The UnlIMMited trial assessed Risankizumab's efficacy and safety for patients with moderate to severe genital and scalp psoriasis. Remarkably, more than 72% to 100% of participants attained a DLQI score of 0 or 1, indicating noteworthy quality of life improvements. Moreover, the results have contributed to recent updates in the official labeling of Risankizumab by the FDA.

Promising Findings in Vitiligo and Alopecia Areata

Additionally, AbbVie is excited to present results from two Phase 3 studies focusing on the evaluation of Upadacitinib for treating non-segmental vitiligo. This will mark the first results from a Phase 3 trial aimed at systemic therapy for vitiligo. In parallel, data from studies assessing Upadacitinib's effects on severe alopecia areata also showed promising outcomes without any new safety signals.

Conclusion

AbbVie's initiatives presented at the AAD 2026 Annual Meeting highlight the company's dedication to advancing treatment options for patients with immune-mediated skin diseases. The studies outlined above not only demonstrate significant clinical effectiveness and safety profiles for their innovations but also emphasize the transformative impact on patients’ quality of life. AbbVie continues to pool its research efforts to help redefine the treatment paradigms for chronic skin conditions.

To discover more about AbbVie's contributions, attend their sessions or view their ePosters available from the event.